| Code | CSB-RA011087MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to BCG-009, targeting the insulin-like growth factor 1 receptor (IGF1R). IGF1R is a transmembrane tyrosine kinase receptor that plays a critical role in cell growth, proliferation, differentiation, and survival through activation of downstream PI3K/AKT and MAPK signaling pathways. Upon binding IGF1 or IGF2, the receptor undergoes autophosphorylation and initiates cascades essential for normal development and metabolism. Dysregulation of IGF1R signaling is implicated in various malignancies, including breast, lung, colorectal, and prostate cancers, where it promotes tumor growth, metastasis, and resistance to therapy. Elevated IGF1R expression is also associated with poor prognosis in several cancer types.
BCG-009 is a reference therapeutic antibody designed to inhibit IGF1R signaling by blocking ligand binding and promoting receptor downregulation. This biosimilar antibody serves as a valuable research tool for investigating IGF1R-mediated pathways, studying receptor biology, and exploring therapeutic mechanisms in oncology research. It enables researchers to examine the role of IGF1R in disease models and evaluate potential intervention strategies.
There are currently no reviews for this product.